INTRODUCTION
Compared with estrogen receptor (ER) and progesterone receptor (PR) negative (ER2/PR2), ER+/PR+ breast cancers have better prognosis and response to the hormone therapies, such as tamoxifen and aromatase inhibitors (1) . A recent study showed that gene expression profiles were different according to the hormone receptor status of breast cancer (2) . Increasing evidence shows that estrogen and progesterone also play a critical role in breast cancer etiology (3) . Early menarche and postmenopausal obesity were more strongly associated with ER+/PR+ than ER2/PR2 cancers (4 -6) .
DNA hyper-/hypo-methylation plays an important role in multistages of breast cancer (7) . Previous studies observed several candidate methylation sites that are associated with the hormone receptor status of breast cancer (8 -10) ; RASSF1A and CCND2 were significantly more methylated in the ER+ than ER2 cancers (10) , whereas the inverse † These authors contributed equally to this study. * To whom correspondence should be addressed: Molecular and Genetic Epidemiology Lab, Department of Preventive Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul 110-799, Korea. Tel: +82 27408326; Fax: +82 27474830; Email: dhkang@ snu.ac.kr correlations were found between hypermethylation of the PGR, TFF1, CDH13, TIMP3, HSD17B4, ESR1 and BCL2 genes and ER expression (8) . Hypermethylation of the ESR1, TGFBR2, PTGS2 and CDH13 genes was associated with PR expression (8) .
To evaluate whether the DNA methylation state is different in the ER and PR status of breast cancer, we performed genome-wide profiling for 12 pairs of ER+/PR+ and ER2/ PR2 breast cancers.
RESULTS
There was no difference in the age, TNM stage and AJCC stage between ER+/PR+ and ER2/PR2 breast cancers (P . 0.4); however, the level of Her2 expression was lower in ER+/PR+ than in ER2/PR2 (P , 0.01) (data not shown).
We identified a total of 148 differently methylated sites (93 hypermethylated and 55 sites hypomethylated) of which the level of methylation was different (P , 0.001). The differently methylated genes were involved in developmental process, signal transduction, oncogenes and immunity genes.
After correction for multiple tests, we found five methylation sites in FAM124B (family with sequence similarity 124B), MANEAL (mannosidase, endo-alpha-like), ST6GAL-NAC1 (alpha6-sialyl-transferase I), NAV1 (neuron navigator 1) and PER1 (period homolog 1) remained significant for the difference in the methylation state between ER+/PR+ and ER2/PR2 breast cancers [ False discovery rate (FDR) , 0.05; Table 1 ]. Of the five genes, we successfully developed methylation-specific PCR (MSP) assays of PER1 and MANEAL and pyrosequencing assays of FAM124B, ST6GAL-NAC1 and NAV1 to validate the data of the genome-wide methylation assay; FAM124B (P ¼ 6.42 × 10
210
) and ST6GALNAC1 (P ¼ 0.02) were significantly hypermethylated in ER+/PR+ breast cancers, NAV1 (P ¼ 4.50 × 10
27
) and PER1 (P ¼ 0.03) were significantly hypomethylated in ER+/PR+ breast cancers, which was concordant with the genome-wide Infinium assay, while the methylation state of MANEAL was not associated with receptor status of breast cancers ( Table 2 and Fig. 1) . Figure 2 from hierarchical clustering showed that ER+/ PR+ cancers were clearly distinguished from the ER2/PR2 cancers. However, one ER+/PR+ sample was co-clustered with the ER2/PR2 group and one ER2/PR2 sample was co-clustered with the ER+/PR+ group.
The most significant gene-network was related to Inflammatory Response and Connective Tissue Disorders, which consist of 13 hypermethylated genes (TLR9, IL8RA, CD28, FCGR, CD22, SORBS3, MAG etc.) and 6 hypomethylated genes (KCNJ9, PLC, FPOR etc.) (Supplementary Material, Fig. S1 and Table S1 ).
DISCUSSION
Using a genome-wide approach, we compared the methylation state of 27 578 sites between 12 pairs of ER+/PR+ and ER2/ PR2 breast cancers, and observed that the methylation state of the five genes (FAM124B, MANEAL, ST6GALNAC1, NAV1 and PER1) is different between the two groups. In a subsequent replication study of these genes, FAM124B, ST6GALNAC1, NAV1 and PER1 were significantly different according to the receptor status of breast cancers.
The PER1 gene is a member of the period family that encoded components of the circadian rhythm of locomotor activity, metabolism and behavior. Previous studies reported that hypermethylation in the PER1 promoter region was inversely correlated with ER expression and a low level of PER1 expression was significantly associated with negative ER status (11 -12) , which is consistent with our result. The methylation site in the PER1 gene found significant for the difference of the methylation state between ER+/PR+ and ER2/PR2 in our study is located in 155 bp upstream of the transcription start point. The ST6GALNAC1 gene is involved in glycosylation of proteins which affect cell -cell interaction, interactions with the matrix and intracellular molecules. Endogenous or exogenous expression of ST6GALNAC1 results in the expression of sialyl-Tn(STn), which is associated with poor prognosis in breast cancer (13) . Our finding that the ST6GALNAC1 gene is hypomethylated at 2 bp upstream of the transcription start point in ER2/PR2 breast cancer may be consistent with biological mechanism. Hypomethylation of the ST6GALNAC1 gene may induce gene expression by activating transcription, because the methylation site was located near the promoter sequence.
The NAV1 gene may be involved in neuronal migration. However, the exact function of this gene is not known. The functions of the other genes (FAM124B and MANEAL) were not known, either.
Several previous studies focused on selected tumor oncogenes and the tumor suppressor genes to reveal the different methylation status between ER+/PR+ and ER2/PR2 cancers (8 -10); a number of the genes including CCND2, APC, ESR1, BCL2, CDH13, PGR, GSTP1, HSD17B4, TGFBR2 and PTGS2 have been reported to be differentially methylated between ER+/PR+ and ER2/PR2 cancers. In our study, none of the genes was differentially methylated when correction for multiple tests was considered (i.e. FDR . 0.05), although four genes (i.e. CCND2, APC, ESR1 and BCL2) were statistically significant before correction for multiple tests (P , 0.05). The inconsistency between the genes identified in our study and those found in the previous candidate gene studies may be due to the issues of statistical power, false positivity, different locus on the same gene and the others.
Our study is the first report of the methylation profile based on a genome-wide methylation approach (.27 000 sites) according to the receptor status in breast cancer. On the other hand, limitations of our study include modest number of sample size and possible false positive results. Correlation between methylation status and gene expression is another issue to be addressed in the further studies.
In conclusion, our study revealed that the methylation status of the FAM124B, ST6GALNAC1, NAV1 and PER1 genes were quite different between ER+/PR+ and ER2/ PR2 breast cancers.
MATERIALS AND METHODS

Sample selection
In the Seoul Breast Cancer Study, a total of 182 tissue samples (85 ER+/PR+ and 97 ER2/PR2) were collected from the patients who had undergone surgery at Seoul National University between 2003 and 2007. In this study, 24 breast cancer samples (12 ER+/PR+ and 12 age-frequency-matched ER2/ PR2) for DNA methylation profiling and 70 breast cancer samples (31 ER+/PR+ and 39 ER2/PR2) for the replication study were randomly selected. The samples were collected in the operating room within 20 min of devascularization; one piece of tissue was immediately sent to the pathologist for examination and the other was stored in liquid nitrogen and stored at 2808C (14) . The study was approved by the Committee on Human Research of the Seoul National University Hospital (IRB No. H-0503-144-004) and informed consent was obtained for use of the breast cancer tissues for research.
Histopathologic analysis
Immunohistochemistry was conducted to determine the ER and PR status. Paraffin-embedded breast cancer tissue blocks were cut into 4 mm sections, deparaffinized in xylene, rehydrated with graded ethanol and then immersed in Tris-buffered saline. Primary antibodies used were anti-ER (Dako Corporation, Carpinteria, CA, USA; 1:50) and anti-PR antibodies (Dako Corporation; 1:50). The primary antibodies were Figure 1 . Results from the replication study of FAM124, ST6GALNAC1 and NAV1 genes using pyrosequencing. The associations between methylation status of the three genes (i.e. FAM124B, ST6GALNAC1 and NAV1) and ER/PR status found from the genome-wide Infinium assay were confirmed in the independent set of 70 breast cancer tissues (ER+/PR+: 31, ER2/PR2: 39).
detected with biotinylated anti-mouse secondary antibody (Zymed Laboratories, San Francisco, CA, USA). ER and PR positivities were defined as the presence of ≥10% positively stained nuclei in 10 high-power fields.
DNA extraction and bisulfate treatment
We isolated the genomic DNA using PureGene kit (Gentra Systems, Minneapolis, MN, USA) and the quantity was determined by PicoGreen dsDNA quantification kit (Invitrogen, Carlsbad, CA, USA). Genomic DNA (500 ml) was bisulfate modified by EZ DNA methylation-Glod kit (Zymo Research, Orange, CA, USA) according to the manufacturer's suggested protocol for the Infinium Methylation Assay.
Methylation profile
A genome-wide methylation profiling of 27 578 methylation sites in 14 000 genes was conducted by an Infinium Methylation Assay that combined the Illumina Infinium Whole Genome Genotyping (WGG) assay and BeadChip technology. The genes include almost 13 000 genes in the NCBI CCDS (http ://www.ncbi.nlm.nih.gov/CCDS) database (Genome Build 36), 144 markers of methylation hotspots in the cancer genes, 982 markers of cancer-related targets and 110 miRNA promoters. One random sample from the 24 samples was hybridized to different chips (technical replicate). We obtained high reproducibility in the technical replicates (r 2 ¼ 0.996).
Replication using MSP
After bisulfate treatment, MSP was performed using the primers specific for methylated PER1 (sense: 5 ′ -GGTTT AGGTA GAGGG TATAT TGTCG TTTTT ATC-3 ′ , antisense:
. MSP was performed in a final volume of 25 ml using 1.25 U Taq (iTaq, Intron Biotechnology, Korea). PCR conditions were as follows: 978C for 5 min; 35 cycles of 958C for 30 s, 598C for 30 s and 728C for 50 s; and final extension of 10 min at 728C. Two microliter PCR products were separated by electrophoresis in 2% agarose gel staining using EtBr (Ethidium bromide) and visualized on UV.
Replication using pyrosequencing
Primers were designed by PSQ Assay Design program v.1.0.6 (Qiagen, Hilden, Germany) and the sequences are presented in Supplementary Material, Table S2 . PCR was performed using bisulfate-treated DNA under the following conditions: 948C for 5 min; 45 cycles of 958C for 30 s, 558C (FAM124B)/ Cluster analysis of methylation level between ER+/PR+ and ER2/PR2 breast cancers (ER+/PR+: P01 P12, ER2/PR2: N01 N12). These sites were selected from the significant different methylated sites with the criteria of P , 0.001 (148 methylation sites). Color scale of the heat map represents densely methylated loci (red) to sparsely methylated loci (green). At the hierarchical clustering, they were clearly clustered into two groups (red and green) with a little error; only one sample was misclassified into the other group, respectively (orange arrow). We obtained 92% specificity (11/12) and 92% sensitivity (11/12) for grouping breast cancers by ER/PR status.
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Human Molecular Genetics, 2010, Vol. 19, No. 21 588C (ST6GALNAC1)/528C (NAV1) for 30 s and 728C for 30 s; and final extension of 5 min at 728C. Pyrosequencing was conducted using PyroMark Gold Q96 Reagents (Qiagen, Hilden, Germany), and PCR was conducted using Accupower HOT start PCR Premix (Bioneer, Daejeon, Korea). Pyrosequencing data were analysed by Pyro Q-CpG V.1.0.9 analysis software (Qiagen, Hilden, Germany), and represented in figure  1 as box plot with mean+SD.
Data analysis
The BeadChip images were scanned by Illumina's iScan system and the data were extracted into BeadStudio software. Background normalization was conducted using the negative control signals from each well (15) . Average normalization was done to minimize scanner-to-scanner variation; the average intensity values of the first color channel for all the wells in each chip were used to calculate mean value, which was scaled to 1. At the end of this procedure, each chip has the same average intensity in each color channel. The level of methylation (b) was determined by the difference between the two intensities fluorescent signals from two probes, i.e. the ratio of methylated-probe signal to total locus signal intensity. The Infinium Methylation Chip data were analyzed with ArrayAssist software. The levels of the methylation (b) difference between ER+/PR+ and ER2/PR2 cancers were compared by Student's t-test. FDR values were calculated using the Benjamini-Hochberg method to consider false positive associations (16) . We considered FDR , 0.05 as being noteworthy.
For clustering and gene-network analysis, we selected 148 methylation sites of which the methylation state was different (P , 0.001) between ER+/PR+ cancers and ER2/PR2 cancers. Hierarchical clustering analysis was based on Euclidean distance matrix and the complete linkage method was performed with an R package. The color scale of the heat map represents densely methylated loci (red) to sparsely methylated loci (green).
Fisher's exact test and Student's t-test were used to examine the difference in methylation status between ER+/PR+ and ER2/PR2 cancers in replication study.
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